Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel technology to monitor ’hidden depths’ of silent killer

02.10.2003


New studies, ASTEROID and ORION, combine CRESTOR™ with cutting-edge imaging techniques, to be at the forefront of the fight against atherosclerosis



Details of two new studies announced by AstraZeneca at the XIIIth International Symposium on Atherosclerosis (ISA) could provide the clearest picture yet of the effects of statins on atherosclerosis, the main cause of coronary artery disease.

Each study is combining the highly effective statin CRESTOR (rosuvastatin) with cutting-edge imaging technology: intravascular ultrasound (IVUS)1 or magnetic resonance imaging (MRI)2,3; to evaluate whether CRESTOR can slow the progression or even lead to a regression of atherosclerosis.


Atherosclerosis gradually narrows the blood vessels, which can lead to a reduction in blood supply to vital organs such as the brain and heart, in some cases this can lead to angina and even a stroke or heart attack. A number of studies have shown that statins may slow the progression or even cause regression of atherosclerosis.4-7 Lowering LDL-cholesterol (LDL-C) slows the progression of atherosclerosis, however, it has been suggested that a larger reduction of at least 40% in LDL-C is needed to observe a regression of atherosclerosis.8,9

Treatment of atherosclerosis should be considered an important target as clinical studies have shown that <1% regression of coronary atherosclerosis is associated with major (70-80%) reductions in clinical events such as heart attacks.10

"Patients with atherosclerosis can show no symptoms for years before experiencing a serious, sometimes fatal, cardiovascular event – often making this disease a silent killer," explained Professor Gunnar Olsson, Vice President and Head of Cardiovascular Therapy Area, AstraZeneca.

"We know that raised LDL-C (or bad cholesterol) and low levels of HDL-C (or good cholesterol) are major risk factors for atherosclerosis and coronary heart disease. CRESTOR can reduce LDL-cholesterol significantly more than the same and some higher doses of other widely used statins and also provides the added benefit of raising HDL-cholesterol or good cholesterol. The three ongoing studies, ASTEROID, ORION and METEOR will demonstrate the benefits of CRESTOR on the atherosclerotic disease process thereby offering the potential for improving the prognosis of patients with, or at risk of, cardiovascular disease – the world’s number one killer."

ASTEROID1 and ORION2, 3, 11 are the first studies to evaluate CRESTOR 40mg – which has been shown to reduce LDL-C by up to 63%12 – on atherosclerosis using the novel imaging technologies IVUS and MRI.

Dr. Steven Nissen, Medical Director of the Cardiovascular Coordinating Center at the Cleveland Clinic Foundation, USA, is the principal investigator on the ASTEROID study. He commented: "Current imaging technology, such as coronary angiography, has only allowed us to visualise the narrowing of the blood vessel caused by atherosclerosis. IVUS lets us see the equally dangerous atherosclerosis hidden within the vessel wall. We are visualising not just the tip of the iceberg, but also what is below the waterline. CRESTOR, compared to other statins, provides outstanding efficacy both in terms of reducing LDL-C (bad cholesterol) and raising HDL-C (good cholesterol). ASTEROID will determine if a maximum dose (40mg) of this particular agent can actually reduce the burden of coronary atherosclerosis during two years of treatment."

"By using non-invasive MRI in ORION we will be able to measure the exact shape, size and distribution of atherosclerosis in blood vessels which may enable us to better evaluate the vascular effects of lipid-lowering therapy, and in clinical practice the use of MRI could facilitate early diagnosis and treatment," stated Dr. Baocheng Chu of the University of Washington School of Medicine, Seattle and investigator for ORION. He continued, "ORION will also show the benefits of CRESTOR in hypercholesterolaemic patients with established atherosclerotic disease."

ASTEROID, which started in November 2002, will recruit 450 patients with coronary artery disease from approximately 60 centres worldwide who will be treated with CRESTOR 40mg once daily for 24 months. The study will measure the percentage change in coronary artery volume at the end of treatment using IVUS. Coronary atherosclerosis will also be assessed using quantitative coronary angiography. 1

ORION has completed recruitment and 39 hypercholesterolaemic patients with established atherosclerosis have been randomised to receive CRESTOR 5mg or 40mg for 24 months. Baseline measurements from patients enrolled in the study were announced at ISA. The change in bilateral carotid artery wall volume will be measured by using MRI. Changes in the intima media thickness of the carotid arteries will also be measured using B-mode ultrasound. 2, 3, 11

METEOR is the third study within the GALAXY Programme evaluating the effects of CRESTOR on atherosclerosis.13 The study which started in August 2002 is using B-mode ultrasound to compare the effects of CRESTOR 40mg or placebo on intima media thickness of the carotid arteries in 840 asymptomatic patients with sub-clinical atherosclerosis who are not routinely treated with statin medication.

CRESTOR has now received regulatory approvals across three continents; America, including the USA, Europe and Asia, and has been launched in several countries worldwide. CRESTOR is awaiting approval in a number of other countries over the coming months.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

AstraZeneca has more than 40 years experience in cardiovascular medicine and aims to increase lifespan and improve quality of life by reducing the risk, prevalence and impact of cardiovascular disease. AstraZeneca has a comprehensive cardiovascular portfolio including CRESTORTM, ATACANDTM, ZESTRILTM, TENORMINTM, SELOKEN ZOK /TOPROL-XLTM and PLENDILTM. This heritage is complemented by an innovative pipeline including the first oral direct thrombin inhibitor, EXANTATM, and a novel treatment for type 2 diabetes / metabolic syndrome, GALIDATM.



For further information please visit: http://www.AstraZenecaPressOffice.com.

Contact:
Julia Walker, Global PR Manager, Cardiovascular Therapy Area, AstraZeneca
Tel: 44-0-1625-510866
Mobile (in Japan): 81-0-90-5340-2294
Mobile: 44-0-7718-80-1984
Email: julia.walker@astrazeneca.com

Ellie Goss or Stephanie Martin, Shire Health International
Tel: 44-0-20-7471-1500
Ellie Goss’s mobile (in Japan): 81-0-90-5340-4799
Email: .goss@shirehealthinternational.com

Stephanie Martin | EurekAlert!
Further information:
http://www.tshg.com/
http://www.AstraZenecaPressOffice.com

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Electrode materials from the microwave oven

19.10.2017 | Materials Sciences

New material for digital memories of the future

19.10.2017 | Materials Sciences

Physics boosts artificial intelligence methods

19.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>